To explore the potentials of methylation analysis of these genes in early detection of GC, the performances of RPRM, RUNX3, RASSF1A, and P16 in early-stage GC patients (I+II) were analyzed in comparison to the controls. The gene discussed is RUNX3; the disease is gastric cancer.